CD4+CD25+ regulatory T cells and their therapeutic potential

Annual Review of Medicine

Volumn 57, Issue , 2006, Pages 381-402

  Randolph, David A ^a   Fathman, C Garrison ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Graft versus host disease; Multiple sclerosis; Suppressor T cell; Type I diabetes

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HLA DR4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CANCER; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

DIABETES MELLITUS, TYPE 1; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-2; MULTIPLE SCLEROSIS; RECEPTORS, INTERLEUKIN-2; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, REGULATORY;

EID: 32944456599     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.57.121304.131337     Document Type: Review

References (90)

1. Powell BR, Buist NR, Stenzel P. 1982. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J. Pediatr. 100:731-37
2. Chatenoud L, Salomon B, Bluestone JA. 2001. Suppressor T cells-they're back and critical for regulation of autoimmunity! Immunol. Rev. 182:149-63
3. Athanassakis I, Vassiliadis S. 2002. T-regulatory cells: Are we re-discovering T suppressors? Immunol. Lett. 84:179-83
4. Dorf ME, Benacerraf B. 1984. Suppressor cells and immunoregulation. Annu. Rev. Immunol. 2:127-57
5. Sakaguchi S, Sakaguchi N, Asano M, et al. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151-64
6. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287-96
7. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-62
8. + cells: a naturally occurring population of regulatory T cells. Blood 98:2736-44
9. +CD25 high regulatory cells in human peripheral blood. J. Immunol. 167:1245-53
10. Ramsdell F. 2003. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19:165-68
11. Gambineri E, Torgerson TR, Ochs HD. 2003. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15:430-35
12. Wildin RS, Ramsdell F, Peake J, et al. 2001. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27:18-20
13. Brunkow ME, Jeffery EW, Hjerrild KA, et al. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27:68-73
14. Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-61
15. + T regulatory cells. Nat. Immunol. 4:337-42
16. + regulatory T cells. Nat. Immunol. 4:330-36
17. Asano M, Toda M, Sakaguchi N, et al. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184:387-96
18. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162:5317-26
19. +CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J. Immunol. 167:188-95
20. Apostolou I, Sarukhan A, Klein L, et al. 2002. Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3:756-63
21. + regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201:127-37
22. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198:1875-86
23. + T cells controlling distinct organ-specific autoimmune diseases. Proc. Natl. Acad. Sci. USA 100:15806-11
24. + regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2:301-6
25. van Santen HM, Benoist C, Mathis D. 2004. Number of T reg cells that differentiate does not increase upon encounter of agonist ligand on thymic epithelial cells. J. Exp. Med. 200:1221-30
26. + T cell receptors. Immunity 21:267-77
27. Malek TR, Bayer AL. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4:665-74
28. Kundig TM, Schorle H, Bachmann MF, et al. 1993. Immune responses in interleukin-2-deficient mice. Science 262:1059-61
29. Sadlack B, Merz H, Schorle H, et al. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253-61
30. Willerford DM, Chen J, Ferry JA, et al. 1995. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521-30
31. + regulatory T cell homeostasis and the maintenance of self-tolerance. J. Immunol. 171:3435-41
32. Suzuki H, Kundig TM, Furlonger C, et al. 1995. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268:1472-76
33. + regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J. Immunol. 173:4994-5001
34. + regulatory T cells. J. Immunol. 172:5287-96
35. Atkins MB. 2002. Interleukin-2: clinical applications. Semin. Oncol. 29:12-17
36. Onizuka S, Tawara I, Shimizu J, et al. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128-33
37. Swiatecka-Urban A. 2003. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Paediatr. Drugs 5:699-716
38. Ndhlovu LC, Takeda I, Sugamura K, et al. 2004. Expanding role of T-cell costimulators in regulatory T-cell function: recent advances in accessory molecules expressed on both regulatory and nonregulatory T cells. Crit. Rev. Immunol. 24:251-66
39. Tai X, Cowan M, Feigenbaum L, et al. 2005. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6:152-62
40. + regulatory T cells. J. Immunol. 171:3348-52
41. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295-302
42. + immunoregulatory T cells: gene expression analysis rev eals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16:311-23
43. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3:135-42
44. + T cells. J. Immunol. 173:5008-20
45. Javelaud D, Mauviel A. 2004. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Int. J. Biochem. Cell Biol. 36:1161-65
46. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969-80
47. + regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194:629-44
48. + regulatory T cell activity in both humans and mice. J. Immunol. 172:834-42
49. + regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J. Exp. Med. 196:237-46
50. + regulatory T cells from human peripheral blood. J. Immunol. 166:7282-89
51. - cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J. Immunol. 172:5213-21
52. + regulatory T cells. J. Exp. Med. 201:737-46
53. + regulatory T cells responsible for protection against diabetes. Proc. Natl. Acad. Sci. USA 101:4572-77
54. + regulatory T cells. J. Exp. Med. 201:1061-67
55. Pestka S, Krause CD, Sarkar D, et al. 2004. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22:929-79
56. + T cells. J. Autoimmun. 16:115-23
57. Roep BO. 2003. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure, Diabetologia 46:305-21
58. Berzins SP, Venanzi ES, Benoist C, et al. 2003. T-cell compartments of prediabetic NOD mice. Diabetes 52:327-34
59. + T cell levels in NOD mice. Proc. Natl. Acad. Sci. USA 99:12287-92
60. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431-40
61. Oregon S, Giarratana N, Smiroldo S, et al. 2003. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 171:4040-47
62. + splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol. 169:2461-65
63. Kukreja A, Cost G, Marker J, et al. 2002. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109:131-40
64. + T-cells from patients with type 1 diabetes. Diabetes 54:92-99
65. Arif S, Tree TI, Astill TP, et al. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113:451-63
66. Jaeckel E, von Boehmer H, Manns MP. 2005. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 54:306-10
67. Chatenoud L. 2003. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3:123-32
68. Herold KC, Hagopian W, Auger JA, et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346:1692-98
69. Belghith M, Bluestone JA, Barriot S, et al. 2003. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9:1202-8
70. Herold KC, Burton JB, Francois F, et al. 2003. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3-gamma1(Ala-Ala). J. Clin. Invest. 111:409-18
71. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. 2000. Multiple sclerosis. N. Engl. J. Med. 343:938-52
72. Chaudhuri A, Behan PO. 2004. Multiple sclerosis is not an autoimmune disease. Arch. Neurol. 61:1610-12
73. Steinman L. 1999. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24:511-14
74. Lucchinetti C, Brack W, Noseworthy J. 2001. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr. Opin. Neurol. 14:259-69
75. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169:4712-16
76. + regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 101:15434-39
77. +CD25 high T regulatory cells and their IL-10 production in multiple sclerosis. J. Neuroimmunol. 144:125-31
78. + T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J. Clin. Immunol. 24:155-61
79. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:971-79
80. Zeiser R, Marks R, Bertz H, et al. 2004. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann. Hematol. 83:551-65
81. Couriel D, Caldera H, Champlin R, et al. 2004. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101:1936-46
82. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196:389-99
83. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9:1144-50
84. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 112:1688-96
85. + T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 105:1828-36
86. + T lymphocytes. Blood 103:4216-21
87. + (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br. J. Haematol. 126:697-703
88. +CD25 high regulatory T cells. Blood 103:2410-16
89. + T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 103:1140-46
90. Miura Y, Thoburn CJ, Bright EC, et al. 2004. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104:2187-93